The DOI matches its Crossref record.
Cost-Minimization Analysis of Trastuzumab Intravenous Versus Trastuzumab Subcutaneous for the Treatment of Patients With HER2+ Early Breast Cancer And Metastatic Breast Cancer in Greece
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Significant cost savings were also seen in various other countries.
“Significant cost savings were also seen in various other countries [7, 8, 44–47].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [46]
Citations
Cited by
Sorted by citations
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
“SC administration costs were also lower for consumables [49, 53, 54, 57, 59, 61–64, 67], drug wastage [67], use of central venous access devices [86], overheads [87], nursing and pharmacy supplies [84], and avoiding catheter implantation surgeries [54] compared with administration costs for IV in all publications that…”
Background
Metadata
- Authors
- Mylonas, C., Kourlaba, G., Fountzilas, G., Skroumpelos, A., & Maniadakis, N.
- Affiliations
- National School of Public Health (GR)
- Aristotle University of Thessaloniki (GR)
- Roche (Greece) (GR)
- Venue
- Value in Health
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 17
- Issue
- 7
- Pages
- A640-A641
- ISSN
- 1098-3015 (ISSN-L)
- OpenAlex
- W2320478156
- Cited by
- 10
- References
- 0
- Citations by year
- 2026: 1 · 2023: 2 · 2022: 1 · 2018: 2 · 2017: 3 · 2016: 1
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Value in Health (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- trastuzumab, subcutaneous administration, intravenous administration, HER2-positive breast cancer, early breast cancer, metastatic breast cancer, cost-minimization analysis, treatment costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
